Ergoteles’s Tenaya Therapeutics TNYA Stock Holding History

Ergoteles’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,261	Closed	-$28.7K	–	1752
2022 Q4	$28.7K	Buy	+14,261	New	+$34.8K	﹤0.01%	1333

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ROTUOC

Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Ergoteles's TNYA Position: Q1 2023 in Review

Ergoteles sold out of Tenaya Therapeutics (TNYA) in Q1 2023, closing a stake of 14,261 shares — an estimated $28.7K sold.

Ergoteles first reported a position in TNYA in Q4 2022 and held it in 1 quarter. The position peaked at $28.7K in Q4 2022. 64 funds tracked by Wall St. Rank hold TNYA as of Q1 2023.

Ergoteles reported no remaining Tenaya Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 14,261 Tenaya Therapeutics shares in Q1 2023, an estimated $28.7K.
Ergoteles first reported a position in Tenaya Therapeutics in Q4 2022 and held it in 1 quarter.
Ergoteles's Tenaya Therapeutics position peaked at $28.7K in Q4 2022.
64 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.